BOJ Policymakers Warn Weak Yen Could Fuel Inflation Risks and Delay Rate Action 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
South Korea Exports Surge in January on AI Chip Demand, Marking Fastest Growth in 4.5 Years 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Russia Stocks End Flat as MOEX Closes Unchanged Amid Mixed Global Signals 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Tabletop particle accelerator could transform medicine and materials science 
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets 
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
China Manufacturing PMI Slips Into Contraction in January as Weak Demand Pressures Economy 
Asian Stocks Waver as Trump Signals Fed Pick, Shutdown Deal and Tech Earnings Stir Markets 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
